Narrow Results

Mesoblast and Lonza Establish Strategic Global Manufacturing Alliance.

Alchemia Announces Initiation of Phase II Trial in Small Cell Lung Cancer.

ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development.

Pfizer And Guoyuan Form Joint Venture To Expand Development, Manufacture And Distribution Of Animal Vaccines In China.

DSM and Sinochem Group Establish Global Anti-infectives Joint Venture.

Trivitron Healthcare Partners with Hitachi Medical Systems.

Agilent Technologies and Chungnam National University Collaborate to Further Glycomics Research.

Bristol-Myers Squibb and Ono Enter into Strategic Agreement.

Clearbridge BioMedics, Abnova Corporation Announce Collaboration.

LAByrinth - Magnifying science through the lens of design and culture.

Determining glycan structures is vital to comprehend cell-matrix, cell-cell, and even intracellular biological events. Glycan sequencing, which determines the primary structure of a glycan using tandem mass spectrometry (MS/MS), remains one of the most important tasks in proteomics. Analogous to peptide de novo sequencing, glycan de novo sequencing determines the structure without the aid of a known glycan database. We show in this paper that glycan de novo sequencing is NP-hard. We then provide a heuristic algorithm and develop a software program to solve the problem in practical cases. Experiments on real MS/MS data of glycopeptides demonstrate that our heuristic algorithm gives satisfactory results on practical data.